Novartis
NEWS
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
The AMR Action Fund is ramping up its infrastructure – announcing yesterday that former Novartis Venture Funds Head, Henry Skinner, will take the helm as the organization’s first chief executive officer.
Novartis managed to bridge the gap between evidence of efficacy and value in this space with a variety of value-based pricing plans developed with regional payers.
The Foundation will offer funding for development of the therapy.
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
While companies around the globe reduce staff amidst economic upheaval, there’s at least one industry on the rise - life sciences. Here’s who’s breaking ground on expansion projects.
JOBS
IN THE PRESS